Jaundice in patients with chronic granulocytic leukaemia may be a rare hepatotoxic side effect of prolonged busulphan therapy rather than disease infiltration.
Jaundice in busulphan-treated chronic granulocytic leukaemia warrants considering drug toxicity; this case report leaves open confirmation in larger cohorts.
This hepatotoxic effect of busulphan ther- apy appears to be rare and in this case was associated with prolonged therapy.However, we suggest that jaundice in patients under treatment for chronic granulocytic leukaemia may be attributable to busulphan therapy rather than severe leukaemic infiltration of the liver.-Weare, etc.,
No takes yet. Share an insight, caveat, or question.
DavidN. Phear (1971) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from BMJ